查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1853418

先進治療藥物CDMO市場按產品類型、服務類型、治療領域、應用和最終用戶分類 - 全球預測（2025-2032年）

Advanced Therapy Medicinal Products CDMO Market by Product Type, Service Type, Therapeutic Area, Application, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，先進療法 CDMO 市場將成長至 284.6 億美元，複合年成長率為 17.71%。

關鍵市場統計數據
基準年2024年 77.1億美元
預計年份：2025年 89.7億美元
預測年份 2032 284.6億美元
複合年成長率（%） 17.71%

本文概述了技術成熟度和業務需求如何再形成CDMO在細胞、基因和組織工程療法領域中的角色，並提出了一個簡潔的策略框架。

先進治療產品（ATMP）合約開發與受託製造廠商（CDMO）產業處於科學創新與工業規模生物加工的交會點。細胞療法、基因療法和組織工程的快速發展正在改變服務供應商的研發路徑和營運預期，並引發分析、製程開發、生產和監管等職能能力的重組。隨著申辦者從發現研究推進到臨床和商業化供應，他們越來越需要能夠將深厚的生物加工專業知識與監管策略、品質系統和可擴展的生產平台相結合的合作夥伴。

本執行摘要總結了目前影響供應商選擇、投資重點和競爭差異化的動態因素。它重點闡述了技術成熟度、監管演變和供應鏈現狀如何推動合約研發生產機構（CDMO）拓展服務範圍並提升專業化水準。本書將科學趨勢與商業需求結合，為領導者提供清晰的觀點，幫助他們明確資源部署方向、優先彌補哪些能力缺口，以及如何調整組織架構以支援小分子生技藥品和複雜工程化藥物的研發。本書旨在幫助決策者將技術洞見轉化為切實可行的策略行動，從而在不影響品質或合規性的前提下，降低專案風險並加快研發進程。

科學創新、監管預期和商業化壓力如何推動CDMO拓展自身能力並建立更深的夥伴關係關係

在科學突破和商業性前景的共同推動下，ATMP（先進治療藥物）領域正發生變革性轉變，迫使CDMO（合約研發生產機構）超越傳統的生產服務模式。載體設計、細胞工程和支架技術的進步增加了製程的複雜性，同時也為實現以往難以企及的持久臨床療效鋪平了道路。因此，CDMO必須平衡對專用無塵室架構和一次性技術的投資，以及對細胞和載體分析的投資，以實現穩健的表徵和可比性。

同時，支付方和監管機構越來越重視長期證據的產生和供應的穩定性，這促使申辦方選擇能夠支持其從早期臨床開發到商業化全生命週期策略的合作夥伴。這種趨勢推動了更深層的策略聯盟，CDMO參與平台開發、監管申報支援和上市後生產保障。這種轉變強調了靈活的能力、數據的完整性和跨職能的計劃管治，成功的供應商展現了降低研發風險、最佳化成本和縮短臨床試驗時間的能力。

因應2025年關稅政策帶來的供應鏈和製造地策略的調整，以維持業務連續性和成本效益。

2025年新關稅的實施為原料採購、專用一次性零件採購和跨境製造服務採購帶來了新的成本和複雜性，相關人員必須應對這些挑戰。關稅主導的成本壓力迫使贊助商和服務供應商重新評估其供應鏈的韌性，實現供應商多元化，並在可行的情況下加快在地化策略。在某些情況下，製造商正在調整採購計劃，優先選擇來源透明且關稅合規記錄良好的供應商，從而減少海關延誤和意外成本轉嫁。

此外，關稅環境正在影響臨床和商業供應的生產能力選址的策略決策。申辦方越來越傾向於權衡集中式高產能生產基地和區域分散式生產模式之間的利弊，後者可以減輕關稅的影響並縮短物流路徑。 CDMO（合約研發生產機構）則透過加強海關專業知識、建立穩健的庫存緩衝以及製定成本分配框架來應對這一挑戰，從而在保持供應可靠性的同時，維持專案的經濟效益。

一種以細分市場主導、細緻入微的視角，展現了產品模式、服務範圍、治療領域、應用階段和最終用戶畫像如何定義CDMO的差異化價值提案。

市場區隔洞察揭示了不同的需求促進因素和產能需求，從而指南產品組合開發和市場推廣策略。依產品類型分類，可分為細胞療法、基因療法和組織工程產品。在細胞療法領域，需求可細分為非幹細胞療法和幹細胞療法；而在基因療法領域，需求則可細分為生殖系基因療法和體細胞基因療法。這些治療方式的差異會影響供應商必須提供的檢測類型和規模、滴度測定以及產品放行檢測，以避免臨床進展風險。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • CDMO的商業化同種異體細胞療法生產能力迅速擴張
  • 整合數位化過程監控和分析，以提高ATMP批次一致性
  • 監管協調工作旨在簡化先進治療方法的全球核准
  • 與生物技術創新企業建立策略性CDMO夥伴關係，以實現產量產量病毒載體的生產。
  • 引入封閉式自動化生產線以降低ATMP污染風險
  • 投資建造靈活的多產品生產設施，以適應各種基因​​和細胞療法。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按產品類型分類的先進治療藥物CDMO市場

  • 細胞治療產品
    • 非幹細胞療法
    • 幹細胞療法
  • 基因治療產品
    • 生殖細胞療法
    • 體細胞基因治療
  • 組織工程產品

9. 按服務類型分類的先進治療藥物CDMO市場

  • 分析測試和品管
  • 製造服務
  • 流程開發服務
  • 監管和合規支持

第10章：按治療領域分類的先進治療藥物CDMO市場

  • 心臟病學
  • 皮膚科
  • 血液學
  • 神經病學
  • 腫瘤學

第11章：按應用領域分類的先進治療藥物CDMO市場

  • 臨床階段
  • 商業階段

第12章：按最終用戶分類的先進治療藥物CDMO市場

  • 學術研究機構
  • 生物製藥公司

第13章：按地區分類的先進治療藥物CDMO市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：按集團分類的先進治療藥物CDMO市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：各國先進治療藥物CDMO市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Abzena
    • Advanced Therapies, LLC
    • AGC Inc.
    • Aldevron
    • Almac Group
    • Bio Elpida by Polyplus
    • BlueReg
    • Catalent Inc.
    • CELONIC Group
    • CGT Catapult
    • Charles River Laboratories International, Inc.
    • Coriolis Pharma Research GmbH
    • Curia Global, Inc.
    • Eurofins Scientific SE
    • FUJIFILM Diosynth Biotechnologies
    • Lonza Group
    • Minaris Regenerative Medicine
    • Oxford Biomedica PLC
    • Patheon by Thermo Fisher Scientific Inc.
    • Recipharm AB
    • Rentschler Biopharma SE
    • REPROCELL Inc.
    • RoslinCT
    • Samsung Biologics
    • VIVEBIOTECH SL
Product Code: MRR-3A2E844FDCF6

The Advanced Therapy Medicinal Products CDMO Market is projected to grow by USD 28.46 billion at a CAGR of 17.71% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.71 billion
Estimated Year [2025] USD 8.97 billion
Forecast Year [2032] USD 28.46 billion
CAGR (%) 17.71%

A concise strategic framing of how technological maturation and operational demands are reshaping CDMO roles for cell, gene, and tissue engineered therapeutics

The advanced therapy medicinal products (ATMP) contract development and manufacturing organization (CDMO) sector sits at the intersection of scientific innovation and industrial-scale bioprocessing. Rapid advances in cell therapy, gene therapy, and tissue engineering are shifting development pathways and operational expectations for service providers, triggering a reframing of capabilities across analytical, process development, manufacturing, and regulatory functions. As sponsors progress from exploratory research to clinical and commercial supply, they increasingly require partners who can integrate deep bioprocess expertise with regulatory strategy, quality systems, and scalable manufacturing platforms.

This executive summary synthesizes current dynamics shaping provider selection, investment priorities, and competitive differentiation. It emphasizes how technological maturation, regulatory evolution, and supply chain realities are driving CDMOs to expand service breadth while enhancing specialization. The narrative connects scientific trends to operational imperatives, offering leaders a clear perspective on where to align resources, which capability gaps to prioritize closing, and how to position organizations to support both small molecule-free biologics and complex engineered modalities. The intent is to help decision-makers convert technical insights into practical strategic actions that reduce program risk and accelerate timelines without compromising quality or compliance.

How converging scientific innovation, regulatory expectations, and commercialization pressures are compelling CDMOs to expand capabilities and form deeper partnerships

Transformative shifts in the ATMP landscape are driven by the confluence of scientific breakthroughs and commercial expectations, pressing CDMOs to evolve beyond traditional manufacturing service models. Advances in vector design, cell engineering, and scaffold technologies are increasing process complexity while simultaneously opening routes to durable clinical responses that were previously unattainable. As a result, CDMOs must balance investments in specialized cleanroom architectures and single-use technologies with investments in cell and vector analytics that enable robust characterization and comparability.

Concurrently, payers and regulators are emphasizing long-term evidence generation and supply consistency, which motivates sponsors to select partners capable of supporting lifecycle strategies from early clinical development through commercialization. This dynamic is fostering deeper strategic alliances where CDMOs participate in platform development, regulatory filing support, and post-market manufacturing assurance. The shift places a premium on flexible capacity, data integrity, and cross-functional project governance, with successful providers demonstrating an ability to de-risk development pathways while optimizing cost and time to clinic.

Navigating the 2025 tariff-driven recalibration of supply chains and manufacturing location strategies to maintain continuity and cost-effectiveness

The imposition of new tariff measures in 2025 has introduced an additional cost and complexity vector that stakeholders must navigate in sourcing raw materials, specialized single-use components, and cross-border manufacturing services. Tariff-driven cost pressures have prompted sponsors and service providers to reassess supply chain resilience, diversifying supplier bases and accelerating localization strategies where feasible. In some cases, manufacturers are reconfiguring procurement plans to prioritize vendors with transparent origin and tariff compliance histories to reduce customs delays and unexpected cost pass-throughs.

Moreover, the tariff environment has influenced strategic decisions around where to locate manufacturing capacity for clinical and commercial supply. Sponsors are increasingly weighing the trade-offs between centralized high-capacity sites versus distributed regional manufacturing models that can mitigate tariff exposure and shorten logistical pathways. Regulatory dossiers and quality systems must be adjusted to reflect multi-jurisdictional production plans, and CDMOs are responding by enhancing customs expertise, implementing robust inventory buffers, and developing cost-allocation frameworks that preserve program economics while maintaining supply reliability.

A nuanced segmentation-driven lens showing how product modalities, service scopes, therapeutic areas, application stages, and end-user profiles define differentiated CDMO value propositions

Segmentation insights reveal differentiated demand drivers and capability requirements that should guide portfolio development and go-to-market strategies. Based on Product Type, the landscape includes Cell Therapy Products, Gene Therapy Products, and Tissue Engineered Products; within cell therapies, demand separates between Non-stem Cell Therapy and Stem Cell Therapy, while gene therapy distinctions arise between Germline Therapy and Somatic Gene Therapy, each pathway carrying unique manufacturing and regulatory considerations. These modality distinctions influence the type and scale of analytics, potency assays, and release testing that providers must offer to de-risk clinical progression.

Based on Service Type, service expectations encompass Analytical Testing & Quality Control, Manufacturing Services, Process Development Services, and Regulatory & Compliance Support, and the most competitive providers integrate these capabilities to provide seamless technology transfer and comparability assessments. Based on Therapeutic Area, the sector spans Cardiology, Dermatology, Hematology, Neurology, and Oncology, with oncology and hematology programs frequently demanding accelerated timelines, complex release criteria, and higher regulatory scrutiny. Based on Application, differentiation between Clinical Stage and Commercial Stage use cases requires flexibility in batch size, facility qualification, and supply chain robustness. Based on End-User, the market engages both Academic & Research Institutes and Biopharmaceutical Companies, which present divergent needs around cost sensitivity, regulatory sophistication, and expectations for long-term manufacturing partnerships.

Taken together, these segmentation axes show that successful service providers must architect modular offerings that can be configured to meet modality-specific analytical demands, therapeutic area nuances, and the distinct operational rhythms of early-stage researchers versus commercial sponsors. This segmentation-informed approach enables targeted investment in platform technologies and quality infrastructures that align with customer priorities and regulatory pathways.

How regional manufacturing ecosystems and regulatory landscapes are influencing sourcing choices and the geographical distribution of advanced therapy production capacity

Regional dynamics are reshaping where sponsors elect to conduct development and secure commercial supply, with geographic strengths and constraints influencing provider specialization and client engagement models. In the Americas, investment into flexible manufacturing and advanced analytics is creating hubs that emphasize speed to clinic for early-phase programs and support for scale-up activities. Talent concentration and established regulatory pathways make the region attractive for complex modality development, but high operational costs incentivize hybrid models that combine domestic capacity with offshore manufacturing for non-core processes.

In Europe, Middle East & Africa, regulatory harmonization efforts and incentives in several jurisdictions support a diverse provider ecosystem that blends academic spinouts with industrial-scale CDMOs. This regional tapestry fosters collaborative innovation but also requires close attention to cross-border regulatory alignment and localized compliance requirements. In Asia-Pacific, rapid capacity expansion, competitive manufacturing cost structures, and growing scientific talent pools are driving an increasing share of clinical and commercial manufacturing activities, though sponsors must carefully evaluate quality standards and supply chain traceability when engaging new partners.

These regional distinctions encourage sponsors to adopt multi-regional sourcing strategies that balance speed, cost, and regulatory security. Providers that can demonstrate validated processes across jurisdictions, harmonized quality systems, and robust logistics will be better positioned to capture cross-border demand and to support clients pursuing global clinical development and commercialization pathways.

An assessment of provider strategies showing how capability consolidation, targeted specialization, and strategic partnerships are shaping competitive advantage in CDMO services

Company-level dynamics are centered on capability integration, platform scalability, and strategic partnerships that bridge scientific development with commercial readiness. Leading providers are investing in end-to-end capability stacks, combining rigorous analytical testing, advanced process development, and regulatory support to present cohesive value propositions for complex cell and gene therapy programs. These investments often pair with targeted alliances, technology licenses, or joint development agreements that accelerate access to specialized vectors, cell expansion platforms, and potency assay technologies.

At the same time, the competitive field includes specialist providers that maintain high-value niches, such as vector manufacturing or bespoke tissue engineering services, which can be highly attractive to sponsors seeking domain-specific expertise. Mergers and acquisitions continue to be a strategic lever for scaling capacity and absorbing specialized know-how, while organic investments in single-use infrastructure and digital quality systems enhance operational responsiveness. For sponsors, the optimal partner selection balances an assessment of technical fit, track record in regulatory submissions, and the provider's governance model for risk sharing and traceability during technology transfers.

Actionable strategies for leaders to enhance resilience, scale capabilities, and forge deeper, risk-aligned partnerships across the advanced therapy CDMO continuum

Industry leaders should adopt a proactive agenda that balances near-term operational resilience with longer-term capability building. Immediate priorities include strengthening supply chain transparency for critical raw materials and single-use consumables, formalizing multi-sourcing strategies to mitigate tariff and logistics exposure, and implementing robust inventory and batch-tracking mechanisms that align with multi-jurisdictional regulatory expectations. Parallel investments in advanced analytics and potency assays will improve comparability and batch release confidence, reducing downstream regulatory friction.

Over the medium term, organizations should prioritize modular facility design and platform standardization to enable rapid scaling from clinical to commercial manufacture. Cultivating strategic partnerships with vector specialists, academic translation centers, and technology licensors can accelerate time-to-clinic while distributing development risk. Leadership should also invest in workforce development programs that build cross-disciplinary expertise in process development, regulatory affairs, and quality systems. Finally, aligning commercial engagement models to offer outcome-linked milestones or shared risk arrangements can differentiate providers and foster deeper, longer-term sponsor relationships that support streamlined development and market entry.

A rigorous mixed-method research approach integrating primary interviews, technical literature review, and capability mapping to deliver validated insights for decision-makers

The analysis underpinning this report synthesizes primary and secondary inputs to produce an evidence-based view of provider capabilities, market dynamics, and operational trends. Primary research included structured interviews with senior leaders across development-stage sponsors, manufacturing executives, process scientists, and regulatory specialists to capture first-hand perspectives on operational priorities and partnership criteria. Secondary sources comprised peer-reviewed literature, regulatory guidance documents, and technical white papers to triangulate technological and compliance trends relevant to advanced modalities.

Analytical methods combined qualitative thematic analysis of interview transcripts with capability mapping and scenario-based risk assessment to evaluate how tariff changes, regional dynamics, and modality complexity influence sourcing and manufacturing strategies. Comparative provider profiling emphasized observable metrics such as facility type, service breadth, historical regulatory interactions, and documented platform technologies. Where possible, the methodology prioritized verifiable, primary-source evidence and cross-validation to ensure findings are robust and actionable for decision-makers seeking to align manufacturing strategies with clinical and commercial objectives.

Strategic imperatives for aligning scientific platforms, manufacturing readiness, and regulatory foresight to support the full lifecycle of advanced therapy programs

Advanced therapy CDMO strategy is increasingly about orchestrating scientific excellence, manufacturing rigor, and regulatory foresight into cohesive partnerships that reduce program risk and accelerate patient access. The combined pressures of technological complexity, tariff dynamics, and regional manufacturing evolution make it imperative for both sponsors and providers to adopt flexible, platform-based approaches and to deepen collaborations that bridge bench science to scalable production. By aligning investments in analytics, modular facilities, and compliance infrastructure with targeted therapeutic area expertise, stakeholders can improve predictability across development stages.

Decision-makers who prioritize transparent supply chains, validated multi-regional capabilities, and shared-risk commercial models will be better positioned to navigate uncertainty while capturing the value of advanced modalities. The path forward is one of selective specialization complemented by interoperable platforms, enabling providers to support the full lifecycle of ATMP programs while maintaining quality and regulatory alignment. This strategic orientation will determine which organizations can reliably serve the complex needs of next-generation therapeutics and sustain long-term partnerships with sponsors.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid expansion of allogeneic cell therapy commercial manufacturing capacity at CDMOs
  • 5.2. Integration of digital process monitoring and analytics to improve ATMP batch consistency
  • 5.3. Regulatory harmonization efforts enabling streamlined global approval of advanced therapies
  • 5.4. Strategic CDMO partnerships with biotech innovators for high-yield viral vector production
  • 5.5. Deployment of closed, automated manufacturing lines to reduce contamination risk in ATMPs
  • 5.6. Investment in flexible multi-product facilities to accommodate diverse gene and cell therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Advanced Therapy Medicinal Products CDMO Market, by Product Type

  • 8.1. Cell Therapy Products
    • 8.1.1. Non-stem Cell Therapy
    • 8.1.2. Stem Cell Therapy
  • 8.2. Gene Therapy Products
    • 8.2.1. Germline Therapy
    • 8.2.2. Somatic Gene Therapy
  • 8.3. Tissue Engineered Products

9. Advanced Therapy Medicinal Products CDMO Market, by Service Type

  • 9.1. Analytical Testing & Quality Control
  • 9.2. Manufacturing Services
  • 9.3. Process Development Services
  • 9.4. Regulatory & Compliance Support

10. Advanced Therapy Medicinal Products CDMO Market, by Therapeutic Area

  • 10.1. Cardiology
  • 10.2. Dermatology
  • 10.3. Hematology
  • 10.4. Neurology
  • 10.5. Oncology

11. Advanced Therapy Medicinal Products CDMO Market, by Application

  • 11.1. Clinical Stage
  • 11.2. Commercial Stage

12. Advanced Therapy Medicinal Products CDMO Market, by End-User

  • 12.1. Academic & Research Institutes
  • 12.2. Biopharmaceutical Companies

13. Advanced Therapy Medicinal Products CDMO Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Advanced Therapy Medicinal Products CDMO Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Advanced Therapy Medicinal Products CDMO Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abzena
    • 16.3.2. Advanced Therapies, LLC
    • 16.3.3. AGC Inc.
    • 16.3.4. Aldevron
    • 16.3.5. Almac Group
    • 16.3.6. Bio Elpida by Polyplus
    • 16.3.7. BlueReg
    • 16.3.8. Catalent Inc.
    • 16.3.9. CELONIC Group
    • 16.3.10. CGT Catapult
    • 16.3.11. Charles River Laboratories International, Inc.
    • 16.3.12. Coriolis Pharma Research GmbH
    • 16.3.13. Curia Global, Inc.
    • 16.3.14. Eurofins Scientific SE
    • 16.3.15. FUJIFILM Diosynth Biotechnologies
    • 16.3.16. Lonza Group
    • 16.3.17. Minaris Regenerative Medicine
    • 16.3.18. Oxford Biomedica PLC
    • 16.3.19. Patheon by Thermo Fisher Scientific Inc.
    • 16.3.20. Recipharm AB
    • 16.3.21. Rentschler Biopharma SE
    • 16.3.22. REPROCELL Inc.
    • 16.3.23. RoslinCT
    • 16.3.24. Samsung Biologics
    • 16.3.25. VIVEBIOTECH S.L.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NON-STEM CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NON-STEM CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NON-STEM CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NON-STEM CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NON-STEM CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NON-STEM CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GERMLINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GERMLINE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GERMLINE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GERMLINE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GERMLINE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GERMLINE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SOMATIC GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SOMATIC GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SOMATIC GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SOMATIC GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SOMATIC GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SOMATIC GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY MANUFACTURING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY MANUFACTURING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY MANUFACTURING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY MANUFACTURING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGULATORY & COMPLIANCE SUPPORT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGULATORY & COMPLIANCE SUPPORT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGULATORY & COMPLIANCE SUPPORT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGULATORY & COMPLIANCE SUPPORT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGULATORY & COMPLIANCE SUPPORT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGULATORY & COMPLIANCE SUPPORT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY DERMATOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY HEMATOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CLINICAL STAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CLINICAL STAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CLINICAL STAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CLINICAL STAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CLINICAL STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CLINICAL STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COMMERCIAL STAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COMMERCIAL STAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COMMERCIAL STAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COMMERCIAL STAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COMMERCIAL STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COMMERCIAL STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC ADVANCED THERAPY MEDICIN